Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein, among other things, is an implantable medical device header assembly with an optical interface. The header assembly can include a housing defining a cavity; an electrical contact disposed along the cavity; an electrical conductor configured to electrically couple the electrical contact with the implantable medical device; and an optical conductor. The header assembly can include a housing defining a first cavity for receiving a proximal end of an electrical lead; and a second cavity for receiving a proximal end of an optical lead. The header assembly can include a housing configured to be coupled to the implantable medical device, the housing defining a lead port for receiving a proximal end of a lead, the port configured to be in electrical and optical communication with the lead; a transducer disposed within the housing, and an electrical conductor disposed within the housing. Other aspects and embodiments are provided herein.

Abstract: A handheld HVAC/R test and measurement instrument having a display, a keypad, a microprocessor, memory, and circuitry adapted to receive inputs from a plurality of sensors and to automatically determine the type of each sensor and automatically determine and display which HVAC/R tests and measurements are available to be performed by the field service technician using only the plurality of sensors. Different kits of sensors are used for various tests and measurements routinely performed when servicing HVAC/R systems, and the handheld instrument automatically identifies the sensors connected to it and leads the technician through the tests and measurements that can be performed using those sensor inputs in combination with technical reference information and calculation algorithms stored in memory.

Abstract: In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments are provided herein.

Abstract: Embodiments of the invention are related to devices and methods for modulating renal function, amongst other things. In an embodiment, the invention includes a method of modulating renal function in a patient including implanting an occlusive device in the patient, the occlusive device comprising a semi-permeable membrane and configured to expand or contract based on the passage of a fluid across the semi-permeable membrane. Other aspects and embodiments are provided herein.

Abstract: In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments are provided herein.

Abstract: Embodiments of the invention are related to devices and methods for modulating renal function, amongst other things. In an embodiment, the invention includes an implantable occlusive device including a wall member defining an enclosed volume, the wall member can include a semi-permeable membrane. The device can also include a solution comprising a solvent and a solute disposed within the enclosed volume of the wall member. The semi-permeable membrane can be permeable to the solvent and impermeable to the solute. The enclosed volume can be configured to expand and contract in response to changes in the osmolality of a bodily fluid. The device can include a positioning member configured to maintain the position of the implantable occlusive device relative to a lengthwise axis of a lymphatic vessel.

Abstract: Embodiments of the invention are related to monitoring devices and methods with osmometric sensors, amongst other things. In an embodiment, an implantable heart failure monitoring system includes an implantable osmometric sensor configured to generate a signal corresponding to osmotic strength of a bodily fluid. The osmometric sensor includes a rigid wall member defining an enclosed volume resisting deformation, the rigid wall member comprising a semi-permeable membrane. The sensor also includes a signaling element comprising a first side, a second side, and a plurality of dimples configured to resist deformation until a threshold differential exists between the first and second sides. Other aspects and embodiments are provided herein.

Abstract: A method of producing a modified pigment by sulfonating a pigment and subsequently oxidizing the pigment. The modified pigment may have sulfonic acid and carboxyl surface modifying groups attached to the surface of the pigment. Charge balancing counterions such as alkali metals, alkaline earth metals and NR1R2R3H+, where R1, R2 and R3 are independently H or C1-C5 alkyl groups, may be associated with the surface modifying groups. The modified pigment is combined with water to produce a dispersion that can be used in such applications as coatings, paints, papers, adhesives, latexes, toners, textiles, fibers, plastics and inks.

Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Embodiments generally disclosed herein include a computer-implemented method for monitoring and correlating network traffic data associated with a primary network that is in communication with a plurality of secondary networks. The method generates a network traffic data set by monitoring network traffic between the primary network and the plurality of secondary networks. The method also determines a mapping of network connectivity by monitoring inter-network routing information between the primary network and the plurality of secondary networks. In addition, the method generates a traffic measurement data set by monitoring network utilization statistics between the primary network and the plurality of secondary networks. With the collected data sets, the method then calculates a relational network mapping between the primary network and the plurality of secondary networks by correlating the network traffic data set, the mapping of network connectivity, and the traffic measurement data set.

Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments are provided herein.

Abstract: Embodiments of the invention are related to monitoring devices and methods with osmometric sensors, amongst other things. In an embodiment, the invention includes an implantable heart failure monitoring system including an implantable osmometric sensor configured to generate a signal corresponding to osmotic strength of a bodily fluid, the osmometric sensor comprising a rigid wall member defining an enclosed volume resisting deformation, the rigid wall member comprising a semi-permeable membrane; a signaling element comprising a first pressure sensor; and a second pressure sensor. Other aspects and embodiments are provided herein.

Abstract: Embodiments of the invention are related to monitoring devices and methods with osmometric sensors, amongst other things. In an embodiment, the invention includes an implantable heart failure monitoring system including an osmometric sensor, the osmometric sensor configured to generate a signal corresponding to the osmotic strength of a bodily fluid, and a controller in communication with the osmometric sensor, the controller configured to receive and process the signal corresponding to the osmotic strength of a bodily fluid. Other aspects and embodiments are provided herein.

Abstract: Embodiments of the invention are related to devices and methods for myocardial ischemia detection, amongst other things. In an embodiment, the invention includes an implantable medical device including control circuitry, an electrical field sensor in communication with the control circuitry, the electrical field sensor configured to generate a signal corresponding to cardiac electrical fields. The implantable medical device can also include a chemical sensor in communication with the control circuitry, the chemical sensor configured to generate a signal corresponding to the concentration of a physiological analyte that affects cardiac electrical field waveform morphology. The control circuitry can be configured to monitor for the presence of myocardial ischemia by evaluating both the signal generated by the electrical field sensor and the signal generated by the chemical sensor. Other embodiments are also included herein.

Abstract: Embodiments of the invention are related to optical window assemblies for implantable medical devices, amongst other things. In an embodiment, the invention includes an optical window assembly for a medical device. The assembly can include a ferrule defining an aperture and a spacer ring disposed within the aperture. The assembly can also include an optical window coupled to the metal ferrule and the spacer ring. In an embodiment, the invention includes an implantable medical device including a housing and an optical window assembly coupled to the housing. In an embodiment, the invention can include a method of manufacturing a medical device. The method can include brazing a spacer ring to a metal ferrule, coupling an optical window to the spacer ring and the metal ferrule with a bonding glass material, depositing a chemical sensing element over the optical window, and coupling a porous cover layer to the spacer ring and the ferrule with an adhesive. Other embodiments are also included herein.

Abstract: A package for a micro-electromechanical device (MEMS package) includes an inner enclosure having an inner cavity defined therein, and a fill port channel communicating with the inner cavity and of sufficient length to allow a quantity of adhesive to enter the fill port channel while preventing the adhesive from entering the inner cavity.

Abstract: A method for identifying VLANs associated with a network includes gathering actual network element configuration data from a plurality of network elements in the network, wherein the actual network element configuration data identifies one or more VLANs that at least some of the plurality of network elements are actually allocated to; correlating the actual network element configuration data with administrative VLAN data; and determining one or more VLANs that are not commonly identified in both the actual network element configuration data and the administrative VLAN data.